

Substitute for form 1449/PTO (Revised 07/2007)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/577,390
				Filing Date	May 29, 2007
				First Named Inventor	Long
				Art Unit	1644
Examiner Name	Not Yet Assigned				
Sheet	1	of	2	Attorney Docket Number	035784/309974

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	14	US-5,397,703	03-14-1995	de Boer <i>et al.</i>	
	15	US-5,677,165	10-14-1997	de Boer <i>et al.</i>	
	16	US-5,801,227 A	09-01-1998	Fanslow, III <i>et al.</i>	
	17	US-5,874,082	02-23-1999	de Boer	
	18	US-6,004,552	12-21-1999	de Boer <i>et al.</i>	
	19	US-6,056,959	05-02-2000	de Boer <i>et al.</i>	
	20	US-6,315,998 B1	11-13-2001	de Boer <i>et al.</i>	
	21	US-6,899,879 B2	05-31-2005	de Boer <i>et al.</i>	
	22	US-20070098717 A1	05-03-2007	Long <i>et al.</i>	
	23	US-20070098718 A1	05-03-2007	Long <i>et al.</i>	
	24	US-20070110754 A1	05-17-2007	Long <i>et al.</i>	
	25	US-20070218060 A1	09-20-2007	Long <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	26	WO 94/01547 A3	01-20-1994	Cetus Oncology Corporation		
	27	WO 95/17202 A1	06-29-1995	Immunex Corporation		
	28	WO 96/18413 A1	06-20-1996	The University of Birmingham		
	29	WO 97/31025 A1	08-28-1997	Chiron Corporation		
	30	WO 99/42075 A2	08-26-1999	Bristol-Myers Squibb Company		
	31	WO 01/34649 A3	05-17-2001	Chiron Corporation		
	32	WO 02/028481 A2	04-11-2002	Chiron Corporation		
	33	WO 02/028905 A2	04-11-2002	Chiron Corporation		
Examiner Signature				Date Considered		

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2007)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/577,390
				Filing Date	May 29, 2007
				First Named Inventor	Long
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	035784/309974

FOREIGN PATENT DOCUMENTS						
	34	WO 02/060485 A2	08-08-2002	IDEC Pharmaceuticals Corporation		
	35	WO 03/045978 A3	06-05-2003	Chiron Corporation		
	36	WO 2005/044294 A2	05-19-2005	Chiron Corporation		
	37	WO 2005/044304 A2	05-19-2005	Chiron Corporation		
	38	WO 2005/044305 A2	05-19-2005	Chiron Corporation		
	39	WO 2005/044306 A2	05-19-2005	Chiron Corporation		
	40	WO 2005/044307 A2	05-19-2005	Chiron Corporation		
	41	WO 2005/044855 A2	05-19-2005	Chiron Corporation		

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	42	BALINT, R, <i>et al.</i> , "Antibody Engineering by Parsimonious Mutagenesis," <i>Gene</i> , 1993, pp. 109-118, Vol. 137, No. 27.	
	43	BOON, L., <i>et al.</i> , "Prevention of Experimental Autoimmune Encephalomyelitis in the Common Marmoset ( <i>Callithrix jacchus</i> ) Using a Chimeric Antagonist Monoclonal Antibody Against Human CD40 Is Associated with Altered B Cell Responses," <i>Journal of Immunology</i> , 2001, pp. 2942-2949, Vol. 167, No. 5	
	44	GISSELBRECHT, C., <i>et al.</i> , "Interleukin-2 Treatment in Lymphoma: A Phase II Multicenter Study," <i>Blood</i> , 1994, pp. 2081-2085, Vol. 83, No. 8.	
	45	LITTLE, M., <i>et al.</i> , "Of Mice and Men: Hybridoma and Recombinant Antibodies," <i>Review Immunology Today</i> , 2000, pp. 364-370, Vol. 21.	
	46	ROSENBERG, S.A., <i>et al.</i> , "A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone," <i>The New England Journal of Medicine</i> , 1987, pp. 889-897, Vol. 316, No. 15	
	47	TAI, Y., <i>et al.</i> , "Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications," <i>Cancer Research</i> , 2004, pp. 2846-2852, Vol. 64, No. 8.	
	48	WENG WEN-KAI, <i>et al.</i> , "Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma," <i>Blood</i> , 2001, p. 466a, Vol. 98, No. 11, Part 1, Abstract #1947.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.